

## San Diego Convention Center



.

h.

final program

COM

san diego

Lead sponsor:



## **Dear Friends:**

On behalf of BIOCOM/san diego and the CALBIOsummit Steering Committee – welcome to CALBIOsummit 2002. With the theme "Advancing the Business of Health" we have put together a program that capitalizes on the necessary elements to move the life sciences industry forward. You will hear compelling sessions on Clinical/Regulatory concerns, the latest developments in Science, and gain powerful insight in the area of Capital Formation.

The general sessions will feature BIOCOM/san diego's Annual Meeting followed by an exciting panel entitled "San Diego – Big Pharma's Land of Opportunity". The Monday Lunch Plenary will include an overview from the Honorable Anthony Principi, Secretary of Veterans Affairs. On Tuesday, during the Closing Lunch, Jim, Morris, known as the 'oldest rookie in baseball history,' will provide for us a motivational tribute on pursuing your dreams. Take time during the day to visit our Exhibit Hall located on the lower level in Hall E, which features 75 exhibits and on Monday, stop by the Career Expo also located in Hall E. We have built in time for valuable networking and socializing throughout each day and during the evening receptions.

This brief letter cannot begin to convey the excitement that we are feeling about CALBIOsummit 2002. We know that this will be a very special meeting for San Diego and the entire California life sciences community. Many thanks to all that have helped in the preparation of this event and to our sponsors and exhibitors for their support. Enjoy.

Sincerely,

**TERRY BRUGGEMAN** Provasis Therapeutics, Inc. CALBIOsummit Chair





GUY IANNUZZI Mentus CALBIOsummit Chair



Vial Nois



JOE PANETTA BIOCOM/san diego President and CEO





GOVERNOR GRAY DAVIS

Dear Friends,

It is a great pleasure to extend a warm welcome to all who have gathered for the CALBIOsummit 2002.

This event is an ideal opportunity for experts in bioscience to exchange ideas about the most pressing issues facing California and the global community. I salute the participants of CALBIOsummit 2002 for encouraging outreach and networking in the field of science.

On behalf of the people of the State of California, I extend best wishes for a successful event.

Sincerely,

GRAY

STATE CAPITOL · SACRAMENTO, CALIFORNIA 95814 · (916) 445-2841

A DEPM



DICK MURPHY MAYOR

## GREETINGS

## TO THE

## CALBIOSUMMIT 2002 PARTICIPANTS

#### April 21-23, 2002

It is with great pleasure that I welcome you to San Diego. We are honored to be the host city for the eleventh CALBIOsummit, the annual west coast conference and trade show for the life sciences industry.

Most people think of San Diego for its seventy miles of beautiful beaches and worldfamous zoo. But we have so much more to experience. You'll discover an international city rich in the arts and culture, nationally recognized theaters, the largest concentration of museums west of the Mississippi and a lively downtown with award-winning restaurants, shops and galleries. San Diego is also home to unique neighborhoods such as historic Old Town, Hillcrest and Mission Valley. When you mix together the warmth of our people with our beautiful natural environment and attractions such as Sea World, Cabrillo National Monument, Mission Bay Park and Seaport Village on San Diego Bay, you are sure to discover why we are becoming known as "A City Worthy of Our Affection."

Please accept my warm wishes for a pleasant and productive stay in San Diego. I am sure you will agree that San Diego is truly a city worthy of your affection. We will happily await your return visit.

Best regards,

Dink Mungh

DICK MURPHY Mayor City of San Diego

CITY ADMINISTRATION BUILDING, 202 C STREET, SAN DIEGO, CALIFORNIA 92101 (619) 238-6330



Welcome to CALBIOsummit 2002 "Advancing the Business of Health." This premier life sciences event is packed with educational opportunities, exhibits specific for the needs of the life sciences industry, a career expo to promote the workforce in San Diego, and many networking opportunities. We hope that you take advantage of the

plenary sessions and fifteen breakout sessions that are geared towards capital formation issues, clinical/regulatory concerns and the latest science drivers that are currently affecting our industry. If you have any questions about the program, please stop by the Registration Desk located outside the Exhibit Hall, or the Information Counter located outside of the Ballroom.

| the second s |
|--|
| 4  |
| 11   |
| 13   |
| 31   |
| 33   |
| 35   |
| 37   |
| 39   |
| 41   |
|  |

#### Schedule at a Glance

| Sunda           | y 4.21.02  |
|-----------------|--|
| 7am - 12pm      | Golf Tournament, Torrey<br>Pines South Golf Course |
| 10am - 4pm      | Exhibit Hall Set Up                                |
| 4:30pm - 6:30pm | Conference Registration                            |
| 5:30pm - 8:30pm | Welcome Reception,<br>Hilton Gaslamp Quarter       |

#### Monday 4.22.02

7:30am Conference Registration 8:30am - 10am Plenary Breakfast: BIOCOM/san diego Annual Meeting and Special **Plenary Session** 10am - 10:30am Networking Break 10am - 7:30pm Exhibit Hall Open 10:30am - 12pm Concurrent Breakout Sessions – Medical Device **Focus in Capital** Formation, Science & Clinical/Regulatory 11am - 4pm Career Expo 12pm - 1:30pm Plenary Luncheon and Keynote Speaker 1:45pm - 3:15pm Concurrent Breakout Sessions: Capital Formation, Science & Clinical/Regulatory

 3:15pm - 4pm Networking Break, Exhibit Hall
 4pm - 5:30pm Concurrent Breakout Sessions: Capital Formation, Science & Clinical/Regulatory
 5:30pm - 7:30pm Exhibit Hall Reception

7pm - 9pm Chairman's Reception Aubergine Grill (By Invitation Only)

#### Tuesday 4.23.02

| 7:30am           | Conference Registration<br>Networking Breakfast in<br>the Exhibit Hall                  |
|------------------|---|
| 7:30am - 11:30am | Exhibit Hall Open   |
| 8:30am - 10am    | Concurrent Breakout<br>Sessions: Capital<br>Formation, Science &<br>Clinical/Regulatory |
| 10am - 10:30am   | Networking Break  |
| 10:30am - 12pm   | Concurrent Breakout<br>Sessions: Capital<br>Formation, Science &<br>Clinical/Regulatory |
| 12pm - 1:30pm    | Closing Luncheon and<br>Keynote Speaker   |

# CALBIO summit

## 4.21.02 SUNDAY

### 7:00am - 12:00pm Golf Tournament, Torrey Pines South Golf Course

The newly renovated Torrey Pines South Golf Course awaits you! This PGA course hosts the Buick Invitational each year, and is a popular spot for golf professionals. Situated atop cliffs towering above the Pacific Ocean, golfers marvel at the views of the coastline and deep ravines.

Sponsored by Frankfurt Bio Tech Alliance

#### 4.22.02 MONDAY

#### 7:30am Conference Registration

## 8:30am - 9:00am Welcome and State of the Industry Address

Baliroom 20ABC Tina S. Nova, Ph.D., CEO, *Genoptix, Inc.* Joseph D. Panetta, President and CEO, *BIOCOM/san diego* 

## 9:00am - 10:00am Plenary Breakfast: BIOCOM/san diego Annual Meeting and Special Plenary Session: "San Diego – Big

Pharma's Land of Opportunity"

### Ballroom 20ABC

Moderator:

Sage Kelly, *UBS Warburg Global Healthcare Group* Panelists: Carolyn Fritz, Global Business Director,

The Dow Chemical Company

Michael R. Jackson, Ph.D., Senior Vice President, Drug Discovery, Johnson & Johnson Pharmaceutical Research and Development Petpiboon Prasit, Ph.D., Executive Director, Medicinal Chen, Merck Research Laboratories -San Diego

Jeff Southerton, Ph.D., M.B.A., Site Head, Strategic Alliances, La Jolla, *Pfizer Limited*  Daniel G. Welch, President, Biopharmaceuticals, Elan Pharmaceuticals Cosponsored by Rudolph & Sletten and Mentus

10:00am - 10:30am Networking Break

10:00am - 7:30pm Exhibit Hall Open Hall E

10:30am - 12 noon Concurrent Breakout Sessions

## Capital Formation – "Financial Communications for the Biotech and Medical Device Industries" Room 25ABC

Clearly articulating a biotech or medical device company's story in a way that is attractive to investors is critical at any point in a company's development – whether it's the B round, the initial public offering (IPO), or follow-on offerings. The panel will address effective positioning with the financial community, including how to effectively communicate in a crowded market without a new window of opportunity for IPOs, how to ensure the business plan and all corporate materials reflect the positioning and appeal to investors, what venture capitalists

## advancing the OUSINCS Sof health

10:00am - 4:00pm Exhibit Hall Set Up

4:30pm - 6:30pm Attendee Registration

#### 5:30pm - 8:30pm

Welcome Reception, Hilton Gaslamp Quarter "Brushstrokes at Sunset"

Enjoy the best part about San Diego – being outside! The Hilton Gaslamp Quarter, just across from the San Diego Convention Center, is the perfect place to be at sunset. Come register early for CALBIOsummit, relax to great music and enjoy networking with friends and colleagues. **Sponsored by La Jolla Pharmaceutical Company** 

and investment bankers are looking for in a company's communications and how effective communications can help biotech companies, both U.S.-based and outside the United States, drive valuation and successful funding efforts. Moderator:

Lynn Rubenson, Senior Vice President, Biotech and Healthcare Practice, *Fleishman Hilliard* Panelists:

Sophia Twaddell, Senior Vice President and Partner/Biotechnology Practice Leader, Fleishman Hilliard

Donald W. Grimm, Venture Partner, HamiltonApex Technology Ventures

Jeffrey L. Riley, Vice President, Strategy and Corporate Development, Ontogen Corporation

### Science – "Medical Device Technology Driving Clinical Diagnostics" Room 24ABC

Diagnostics is an industry that is the front end to drug delivery and therapeutics. A variety of companies and technologies are transforming diagnostics, impacting reproductive medicine, cardiovascular, infectious disease and cancer detection. Recent events are driving government funding in this sector. Several CEOs will discuss the drivers in clinical diagnostics, including the impact of the new legal and political healthcare environment. Moderator:

Paul A. Stewart, Partner, Foley & Lardner

#### Panelists:

V. Randy White, Ph.D., Chief Executive Officer, *Nanogen, Inc.* 

Bruce A. Huebner, Executive Vice President and Chief Operating Officer, *Gen-Probe Inc.* S. Wayne Kay, President and Chief Executive Officer, *Quidel Corporation* 

David M. Sheehan, Co-Chief Executive Officer and President, *Digirad Imaging Solutions, Inc.* 

### Clinical/Regulatory – "Medical Devices and Tools in Drug Discovery" Room 23ABC

Pharmaceutical drug development relies on the discovery process which can be accelerated by technologies that identify and facilitate target selection and drive lead optimization. A variety of technologies, many from the high technology industries, are expediting this process by identifying and stratifying patient populations and measuring the effectiveness of drugs in clinical trials. This panel will discuss the technology issues driving drug discovery.

Panelists:

John Chiplin, Ph.D., President and CEO, GeneFormatics, Inc.

Tina S. Nova, Ph.D., Chief Executive Officer, Genoptix, Inc.

Toni Schuh, Ph.D., President, Chief Executive Officer, SEQUENOM, Inc. Harry Stylli, Ph.D., President, Aurora Biosciences Corporation

### 11:00am - 4:00pm Career Expo Hall E

The Career Expo at CALBIOsummit offers a forum where recruiters and hiring managers are immediately accessible. With a wide array of the leading life sciences companies exhibiting, the Expo has a variety of positions available in both scientific and non-scientific disciplines.

#### Keynote Spotlight



Luncheon Keynote -Anthony Principi, Secretary of Veterans Affairs

#### Keynote Spotlight



Luncheon Keynote -Michael E. Lehman, Executive Vice President of Corporate Resources, CFO and Corporate Executive Officer, SunMicrosystems

## CALB summ

## 4.22.02 MONDAY CONTINUED

12:00pm - 1:30pm Plenary Luncheon Ballroom 20ABC "On the Shoulder of Giants: The Past, Present and Future of VA Research"

#### **Keynote Speakers:**

Anthony Principi, Secretary of Veterans Affairs "Partners for Life"

Michael E. Lehman, Executive Vice President of Corporate Resources, CFO, and Corporate Executive Officer, SunMicrosystems **Cosponsored by Gray Cary Ware &** Freidenrich LLP and Marsh, Inc.

#### 1:45pm - 3:15pm Concurrent Breakout Sessions

## Capital Formation – "Biotech-to-Biotech: Models for Collaboration" Room 25ABC

Big Pharma has historically reached into its deep pockets for the financial wherewithal to access new technologies and drugs by acquiring smaller biotech companies. Recently, though, a new trend has developed whereby biotech companies are increasingly buying other biotech companies. This industry consolidation is being driven by strategy, allowing companies to pool their resources to build scale, augment research and development, enhance sales, and fill up their product pipelines. With more than 1,400 biotech companies in North America and a comparable number in Europe - more consolidation is inevitable, especially as the public equity markets remain volatile and VCs continue to be hesitant to fund unproven companies and technologies. This session will address the trend in biotech-to-biotech mergers, acquisition strategies and collaborations and will include a discussion of the partnering models biotech companies use to share their

technologies to expand their platforms and fortify their pipelines. Speakers include industry executives who have been active in the development of such models. They will share their experiences in the structuring and maintaining of these deals to ensure maximum success. Moderator:

Stephen C. Ferruolo, Shareholder, Heller Ehrman White & McAuliffe, LLP Panelists: Katherine S. Bowdish, Ph.D., President,

Alexion Antibody Technologies, Inc. Michael Grey, Chief Business Officer, Structural GenomiX Richard A. Kaufman, Shareholder,

Heller Ehrman White & McAuliffe, LLP and Former General Counsel, Trega Bioscience

## Science – "Chemical Genomics – Linking Drug Activity with Protein Function"

Room 24ABC

t

To improve success rates in development and speed discovery, scientists are now focused on finding ways to study protein target-small molecule interactions systematically and rapidly. Chemical genomics directly probes the interactions of bioactive compounds, closely linking small molecule activity with protein function. This approach uses small molecule drugs as probes to find new targets and to understand and predict compound effects in the body. Understanding and predicting these protein-compound interactions on a large, genome-wide scale will allow for a better assessment of drug target quality and the predictive assessment of compound safety. Moderator:

Bassil I. Dahiyat, Ph.D., President and CEO, *Xencor* Panelists: Leslie J. Browne, Ph.D., COO, Iconix Pharmaceuticals, Inc. John W. Kozarich, Ph.D., President, CEO, and CSO, ActivX Biosciences

## Clinical/Regulatory – "The FDA Appeals Process"

#### Room 23ABC

The FDA appeals process is a relatively unknown and under-utilized way to mediate disputes with the FDA. Participants will be shown how the FDA appeals process works including the regulations regarding when it is an appropriate option for companies to consider. An FDA representative will provide insight from the FDA's perspective and an attorney will address possible outcomes and ramifications of the process. Moderator: Gerald J. Yakatan, Ph.D., President and CEO, *AVANIR Pharmaceuticals* Panelist:

Larry R. Pilot, Partner, McKenna & Cuneo, LLP

## 3:15pm - 4:00pm Networking Break Hall E Sponsored by CropLife America

4:00pm - 5:30pm Concurrent Breakout Sessions

## Capital Formation – "Sources of Early Financing for Biotech Startups" Room 25ABC

This panel, featuring experienced investors and entrepreneurs, will explore the strategies for identifying and evaluating sources of earlystage financing for biotech startups, including angel and venture investments and private and governmental grants. Topics will include how to position a startup to maximize investor interest among the possible sources of early-stage



#### 4.22.02 MONDAY CONTINUED

financing. This panel also will address the technologies and types of biotech companies that currently are attracting early-stage financing. Moderator:

Carlos D. Heredia, Partner, *Morrison & Foerster* Panelists:

Sydney G. Edwards, Ph.D., Principal, *TL Ventures* Robert Leach, President and COO, *Tenex Greenhouse Corporation* Anthony F. Maida, President and CEO, *Replicon Technologies, Inc.* Robert W. Overell, Ph.D., General Partner, *Frazier & Company* Kenneth J. Widder, M.D., General Partner,

Windamere Venture Partners

## Science – "Immunotherapy of Cancer"

#### Room 24ABC

Immunological approaches are rapidly finding their way to becoming standard therapeutic modalities in the treatment of cancer. In this presentation we will feature advances made by local organizations in the immunotherapy of cancer. Such therapies benefit from greater selectivity for cancer cells without the deleterious side effects associated with chemotherapy. In this presentation, two speakers representing The Scripps Research Institute and IDEC Pharmaceuticals will discuss antibody-based therapy (i.e. passive immunotherapy) and two speakers representing CancerVax and Favrille will discuss therapeutic vaccines (i.e. active immunotherapy). Following the presentations there will be a Q&A session with the panel of speakers. Moderator: Ivor Royston, M.D., Managing Member,

Forward Ventures

### Panelists:

Daniel P. Gold, Ph.D., Executive Vice President of Research and Development, *Favrille, Inc.* David F. Hale, CEO, *CancerVax Corporation* Nabil Hanna, Ph.D., Vice President Research, *IDEC Pharmaceuticals Corporation* Ralph A. Reisfeld, Ph.D., Member, *Scripps Research Institute* 

# Over Your Head When it Comes to Risk Solutions?



4445 Eastgate Mall, Suite 300 San Diego, CA 92121 858-552-4200 www.marsh.com

## Let Us Throw You a Line

Marsh's Life Sciences Practice is dedicated to identifying and validating critical client/industry issues, and developing solutions that make our clients more successful. Guided by your strategic business objectives, we put our experience in the Life Sciences to work for you. Customized successful solution services— that is the Marsh difference.



7

# TTA

## 4.22.02 MONDAY CONTINUED

CALB

m

m

u

## Clinical/Regulatory – "Electronic Documents to Speed Development – From Bedside to Approval" Room 23ABC

This presentation and panel discussion will provide an understanding of the capabilities, issues and potential of electronic documentation in clinical data capture and preparation of regulatory authority submissions. Topics that will be discussed include: how to successfully transition large organizations from paperbased data collection to electronic data capture, how small companies can leverage electronic tools to streamline worldwide marketing application submission, and an FDA opinion on whether these efforts will help

shorten the time to approval. Moderator: David A. Shapiro, M.D., MRCP, FFPM, Executive Vice President, Chief Medical Officer, Idun Pharmaceuticals, Inc. Panelists: Jeffrey A. Green, PharmD., President and CEO, DATATRAK International John F. Wood, M.B.A., RAC, Director, Regulatory Affairs, Amylin Pharmaceuticals, Inc. Antoinette Azevedo, President, e-submission Solutions Jeffrey Klofft, M.S., Vice President, Products and Technology, Phase Forward, Inc. Michael V. Ward, M.D., D.V.M., Vice President, Clinical Affairs, Provasis Therapeutics, Inc.

## Exhibit Hall Reception

#### **Exhibit Hall E**

5:30pm - 7:30pm Sponsored by Celgene Corp., Signal Research Division

#### Chairman's Reception\*

#### "Fly Me to the Moon"

\*7:00pm - 9:00pm (by invitation only) Aubergine Grill 500 Fourth Street, Gaslamp Quarter Sponsored by Heller Ehrman White & McAuliffe LLP


No two companies are alike. That applies to professional service firms, too. At Deloitte & Touche, our people are what make us different. They bring diverse perspectives, multidisciplinary tactics and far-reaching experience to every project for every client we serve. What's more, our teams have developed proprietary systems and techniques that no other firm offers. At Deloitte & Touche, our people are the difference your company needs. For more information, please contact John Moulton, partner-incharge, Life Sciences practice, at (619) 232-6500 or sdmarketing@deloitte.com.

We're as different from our competition as you are from yours.

Deloitte

For Life Sciences services the answer is the **people** of Deloitte & Touche & Touche Assurance & advisory, tax and consulting services www.deloitte.com/us 701 "B" Street, Suite 1900 • San Diego, CA 92101

©2002 Deloitte & Touche LLP Deloitte & Touche refers to Deloitte & Touche LLP and related entities.



4.23.02 TUESDAY

7:30am ~ 8:30am Conference Registration and Networking Breakfast Hall E

7:30am - 11:30am Exhibit Hall Open Hall E

#### 8:30am - 10:00am Concurrent Breakout Sessions

## Capital Formation – "Class Action Litigation and Prevention"

#### Room 25ABC

This panel discussion will deal with the risks of litigation that frequently accompany becoming a public company. It will focus on securities class action litigation, which sometimes arises from initial public offerings and/or market volatility in the aftermarket, as well as a brief discussion of consumer class action and mass tort litigation against biotechnology/pharmaceutical companies based on theories of false advertising or consumer fraud. The discussion will also address directors and officers liability insurance for these risks and corporate indemnification. Moderator:

Shirli Fabbri Weiss, Partner, Litigation, Gray Cary Ware & Freidenrich LLP Panelists:

Darren J. Robbins, Partner, Milberg Weiss Bershad Hynes & Lerach LLP

Adam Werner, Ph.D., Senior Consultant, NERA Economic Consulting

Dana Kopper, CIC, ARM, Senior Vice President, Marsh USA Inc.

## Science – "Human Cloning Research and Applications: Scientific, Ethical, and Policy Issues" Room 24ABC

This panel will present views from academic, government and industry on human therapeutic and reproductive cloning as well as debate the consequences of any new federal regulatory policies for human cloning research. Topics that will be discussed include: "Stem Cells and the Therapeutic Cloning Debate,""Potential Impact of Cloning Regulation on Discovery and Development of New Therapeutics,""The Role of National **Bioethical Advisory Boards in Controversial** Human Biomedical Research and Implications for Cloning Research,""A Moral Basis for Human Reproductive Cloning," and "FDA Oversight of Human Cloning Research." Moderator:

Edward W. Holmes, M.D., Vice Chancellor for Health Sciences and Dean of the School of Medicine, UC San Diego

Panelists:

Lutz B. Giebel, Ph.D., President and CEO, *CyThera, Inc.* 

Lawrence S. B. Goldstein, Ph.D., Professor of Cellular and Medicine, UC San Diego Radhika Rao, J.D., Professor of Law, University of California Hastings College of the Law

## Clinical/Regulatory – "Genomics and New Drug Discovery - If Not Now, When?"

#### Room 23ABC

Unlocking the human genome was supposed to unleash the power of genomics and proteomics into the field of drug discovery. Pharmacogenomics and personalized medicine were the new buzz words. Drugs could be tailored and side effects avoided. Misplaced expectations, mistimed expectations, or both? What is the real story? This panel will explain where we are today, identify the areas most likely to benefit from the genomics revolution, and offer insights into the timing. Moderator:

Bernard D. King, M.D., Principal, Macnas Consulting International Panelists: Janice H. Kurth, M.D., Ph.D., Human Genetics/Pharmacogenetics Roy E. S. Bullingham, M.D., Vice President, Pharmacia Corporation J. Gordon Foulkes, Ph.D., EVP Research and Development, Elitra Pharmaceuticals

### 10:00am - 10:30am Networking Break Sponsored by Andersen, LLP

10:30am - 12:00pm Concurrent Breakout Sessions

## Capital Formation – "Global Financing: How to Successfully Manage International Partnerships"

#### Room 25ABC

Partnering with international investors can pose a number of challenges to biotech companies. This panel of experts will discuss how to manage cross-cultural business relationships. Why should a company seek international investors? What are the tax benefits of international partnerships? What are the legal obstacles? How do you best structure the partnership agreement? How do you manage differing communication styles and expectations? This panel will explore all of these questions and more. Moderator:

Maurice S. Emmer, Partner, *Deloitte & Touche LLP* Panelists:

M. Wainwright Fishburn, Jr., Partner, Cooley Godward LLP



O

# 4.23.02 TUESDAY CONTINUED

S

u

CALBI

m m

Rodney D. Altman, M.D., Partner, *TVM Management* Frank Tufaro, Ph.D., Managing Director, *Medigene, Inc.* Toshifumi Watanabe, Ph.D., President and CEO, *Takada Research Investment, Inc.* 

### Science – "New Approaches to Brain Research"

#### **Room 24ABC**

The complexity of the connections and functions of the central nervous system have demanded the most sophisticated methods for analysis of brain biology. New advances in technology have enabled much more detailed studies on the three-dimensional circuitry within the brain. Open system gene profiling methods have led to molecular dissections of brain region anatomy, and identification of alterations in gene patterns associated with neurological diseases. In combination with evolving models of CNS disease, we can expect accelerating advances in the understanding of brain functions in health and disease. Moderator:

Floyd E. Bloom, M.D., Chief Executive Officer, *Neurome, Inc.* 

Topic: "Gene expression mapping in the CNS"

#### Panelists:

t

Julie A. Ellison, Ph.D., Program Coordinator, Neuroscience Integrative Biology, *Digital Gene Technologies, Inc.* 

Topic: "TOGA\* Gene expression profiling in neurological disease models" Christopher J. Winrow, Ph.D., Laboratory of

Genetics, The Salk Institute for Biological Studies Topic: "Analysis of gene expression in the CNS" Dora Games, Ph.D., Principal Scientist, Elan Pharmaceuticals

Topic: "Model approaches to neurodegenerative disease"

## Clinical/Regulatory – "Doctors and Lawyers Working Together in the Clinical Research Process is not an Oxymoron"

#### Room 23ABC

This panel will provide a debate of the question, are there too many or too few lawyers in the clinical research process? Representatives from industry companies and law firms will offer their insights.

Moderators:

Diane Romza-Kutz, J.D., L.L.M., Partner, Mayer, Brown, Rowe & Maw Anthony W. Fox, M.D., Ph.D., FFPM, FIBiol, Pharmaceutical Physician, President, *EBD Group* Panelists: David A. Shapiro, M.D., MRCP, FFPM, Executive VP and Chief Medical Officer, *Idun Pharmaceuticals, Inc.* David W. Nassif, B.Sc., J.D., Principal, *Strategic Consulting Services* 

## 12:00pm - 1:30pm Closing Luncheon -- "The Importance of Dreams" Ballroom 20ABC

Keynote Speaker: Jim Morris Cosponsored by Brobeck Phleger & Harrison and Sun Microsystems

#### Keynote Spotlight



Luncheon Keynote -Jim Morris, The Oldest Rookie in Major League Baseball

Jim Morris' Cinderella story is testimony to the power of dreams and their ability to inspire and transform human life. At the age of 35, Jim was offered a major league baseball contract, some 11 years after retiring from the minor leagues. Join Jim as he shares his captivating and inspiring tale about the importance of dreams.

#### Special thanks to our Track Sponsors:

Capital Formation
Deloitte & Touche and Morrison & Foerster, LLP

Clinical/Regulatory Mayer, Brown, Rowe & Maw

Science Foley & Lardner

| Monday Breakfast Plenary                               | Monday Lunch Plenary                         | Tuesday Lunch Plenary   |
|--|--|---|
| mentus   | <b>GRAYCARY.</b><br>TECHNOLOGY'S LEGAL EDGE® | Brobeck   |
| RUDOLPH AND SLETTEN                                    | Marsh<br>An MMC Company                      | ATTORNEYS AT LAW  |
| Exhibit Hall Reception                                 | Welcome Reception                            | Golf Sponsor  |
| Celgene  | LJP<br>La Jolla Pharmaceutical Company       | Frankfurt Bio Tech Alliance   |
| Capital Formation<br>Track Sponsors<br><b>Deloitte</b> | Science Track Sponsor                        | Clinical/Regulatory<br>Track Sponsor  |
| & Touche<br>More For<br>More for the global accompt    | FOLEY LARDNER<br>ATTORNEYS AT LAW            | BROWN<br>ROWE<br>& MAW  |
| Sponsor<br>SpoSpace                                    | Supporting<br>Funiture Rental Siegfried      |   |
| IDEC<br>Pastmasseulleals Eurgereilies                  |  |   |
| Affiliate S  | ponsors                                      | Media Sponsor   |
| CancerVax Co<br>Ernst & You<br>Genopti<br>IBM Corpo    | orporation<br>ung, LLP<br>x, Inc.<br>oration | the Sector  |
|  | Intentus                                     | mentus   RUDOLPER SLETTEN   Exhibit Hall Reception   Keigene   L/P   L/P   L/P   L/P   Lotal Pharmaceutical Company   Science Track Sponsor FOLEY : LARDNER Sponsor Supporting Sponsor Sp |



## Frankfurt Bio Tech Alliance



## Frankfurt Bio Tech Alliance – Your Link to the European Life Science Market:

- Big Pharma
- Industry and Research Networks
- Center of Scientific Excellence
- Research & Industrial Parks
- VC & Financial Center
- Legal Services

Frankfurt Bio Tech Alliance

Booth 304 & 306 Cell: +49 175 93 11 949 E-mail: st@frankfurt-business.de www.frankfurt-business.de



#### **Keynote Speakers**



MICHAEL E. LEHMAN, Executive Vice President of Corporate Resources, CFO, and Corporate Executive Officer Michael Lehman holds management responsibilities for Sun's finance, legal, real estate, and information resources functions. He is also a member of Sun's Executive Committee. Prior to his promotion in 1998, Lehman served as Sun's chief financial officer for four years. During his tenure Sun investors acknowledged a 25-fold increase in Sun's market value as Lehman developed Sun's business and financial model. Michael Lehman brings extensive experience in accounting and finance to his position. Previously, he served as vice president and corporate controller of Sun, responsible for the preparation of the company's public financial information, such as quarterly earnings reports and annual reports, as well as overseeing the financial staff of the company's operating subsidiaries. He also coordinated the company's outlook and budgeting processes. Since joining Sun in 1987, Lehman was the director of finance and administration for Sun's Asian subsidiaries based in Hong Kong, and also served as an assistant corporate controller and external reporting manager. Before coming to Sun, Lehman was a senior manager in the San Francisco office of Price Waterhouse, the international accounting firm. In that capacity, he was responsible for audits of multinational entities and performed a variety of financial consulting services. Lehman received a bachelor's degree in business administration from the University of Wisconsin in 1974. He sits on the Dean's Advisory Board of the Graduate School of Business at the University of Wisconsin, Madison, and is a member of the Board of Directors of MGIC Investment Corporation.

#### **JIM MORRIS**



Jim Morris' Cinderella story is testimony to the power of dreams and their ability to inspire and transform human life. His story is the subject of the upcoming film from Walt Disney, "The Rookie," starring Dennis Quaid. Jim's dream was to become a major league baseball player, but his career was derailed by a series of debilitating arm injuries before he got out of the lower minors in 1988. Instead, Jim got married, raised a family of three, and got his college degree before becoming a high school science teacher and baseball coach. At the age of 35 and some 11 years after retiring from minor league baseball, Jim was giving a speech to his high school team about the importance of dreams and hard work when his high school players challenged him to pursue his dream of pitching in the major leagues. Jim made the following bet with his high school team: if they won the District Championship for their division, he would try out for the first major league tryout, where he miraculously threw 12 consecutive pitches at a rate of 98 mph, almost 10 mph harder than he had some 15 years earlier! Inspired by his family and students, Jim immediately signed a professional baseball contract. After pitching for the Tampa Bay Devil Rays in 2000, Jim signed with the Los Angeles Dodgers and retired from baseball in 2001. Join Jim on Tuesday, April 23 at 12pm as he shares his captivating and inspiring tale about the importance of dreams.

#### ANTHONY J. PRINCIPI, Secretary of Veterans Affairs



Anthony J. Principi was nominated to be Secretary of Veterans Affairs by President George W. Bush on December 29, 2000, and was confirmed by the Senate on January 23, 2001. As Secretary, Mr. Principi directs the federal government's second largest department, responsible for a nationwide system of health care services, benefits programs, and national cemeteries for America's veterans and dependents. With a budget of more than \$51 billion, VA employs approximately 219,000 people at hundreds of VA medical centers, clinics, benefits offices, and national cemeteries throughout the country. Prior to his nomination, Mr. Principi was president of QTC Medical Services, Inc., a group of professional service companies providing independent medical examinations and administration. During the past decade, he was senior vice president at Lockheed Martin IMS, and a partner in the San Diego law firm of Luce, Forward, Hamilton & Scripps. A combat-decorated Vietnam veteran, Mr. Principi has worked on national policy issues and has held several executive-level positions in federal government throughout his career. Mr. Principi is a 1967 graduate of the U.S. Naval Academy at Annapolis, Md. He earned his law degree from Seton Hall University in 1975 and was assigned to the Navy's Judge Advocate General Corps in San Diego, Calif. In 1980, he was transferred to Washington as a legislative counsel for the Department of the Navy.

# Whose Baby Is It?

It's your idea, your baby. So it means everything to you. The best way to protect your baby is with the support of a law firm that understands the complexities of intellectual property and biotechnology. Gray Cary's attorneys are technology, business and legal specialists with offices in the center of the burgeoning biotech world. They understand biotechnology and the life sciences. Moreover, Gray Cary appreciates the industry's enormous potential for improving our lives. Gray Cary. Technology's Legal Edge. In San Diego, please contact Lisa Haile or Mark Wicker at 858.677.1400.

GRAYCARY. TECHNOLOGY'S LEGAL EDGE®

Washington, DC

Seattle


Sacramento

Austin

San Francisco

an Diego

Silicon Valley



www.graycary.com

## Plenary Session Panelists: "San Diego: Big Pharma's Land of Opportunity"



#### CAROLYN FRITZ, Global Business Director, The Dow Chemical Company

Carolyn Fritz is the Global Business Director of Dow's Industrial Biotechnology and BioPharmaceutical Manufacturing. She has been in this position since 1999 when she joined Dow. The Industrial Biotechnology and BioPharmaceutical Manufacturing Business Unit currently includes three businesses: Plant Biopharmaceutical Manufacturing, Biomaterials, and Innovase, a Joint Venture with Diversa in industrial enzymes. In addition to these three businesses, Carolyn also leads Dow's biotechnology new business development activities. Carolyn has an M.B.A. from the Wharton School of the University of Pennsylvania, an MS from George Washington University, and a B.S. in Engineering from Iowa State University.

## MICHAEL R. JACKSON, Ph.D., Senior Vice President, Drug Discovery, Johnson & Johnson Pharmaceutical Research and Development



Michael Jackson was trained at the Biochemistry Department at the University of Dundee, Scotland, where he received his Ph.D. in Molecular Toxicology. He completed postdoctoral work at The Scripps Research Institute where he made contributions to our basic understanding of the signals involved in intracellular trafficking of proteins and the cell biology of antigen presentation to T cells. In addition, he was part of the team that solved the first crystal structures of MHC class I and T-cell receptor. Dr. Jackson has been with J&J since 1994. He is currently the Senior Vice President of Drug Discovery representing three U.S. sites. He has played a major role in the La Jolla expansion, where it has quadrupled in size.



PETPIBOON (PEPPI) PRASIT, Ph.D., Executive Director, Medicinal Chen, Merck Research Laboratories - San Diego Peppi Prasit is the Head of Chemistry at Merck Research Laboratories in San Diego. Prior to this, he was a Senior Director of Chemistry at Merck Frosst Centre for Therapeutic Research in Montreal, Canada, where he did his research on leukotrienes and cyclooxygenase 2. He obtained his undergraduate degree from University College London, UK. He received his Ph.D. in organic chemistry from Victoria University of Wellington, New Zealand, and was a post-doctoral fellow at Princeton University. His main research interests are in the fields of inflammation, neurological diseases and osteoporosis. He is a co-inventor of Vioxx.



#### JEFF SOUTHERTON, Ph.D., M.B.A., Site Head, Strategic Alliances, La Jolla, Pfizer Limited

Jeff Southerton is responsible for Pfizer's Strategic Alliances group in La Jolla. Strategic Alliances work closely with Pfizer scientists to identify potential collaborative opportunities with academic groups/biotechnology companies worldwide; negotiate the terms of such interactions; manage ongoing business aspects; and ensure that collaboration goals are met. Jeff is a pharmacologist by training and has held a number of positions within Pfizer over the last 11 years.



#### DANIEL G. WELCH, President, Biopharmaceuticals, Elan Corporation plc

Dan Welch joined Elan as President of Elan Biopharmaceuticals in October, 2000. He is responsible for all activities of Elan's Biopharmaceutical business throughout the world. Before coming to Elan, Mr. Welch spent over 22 years in the pharmaceutical industry. He has lived and worked in the U.S.A., Canada, Europe and is now based in Dublin. His areas of experience are sales and marketing, business development, international marketing and general management. Most recently, he spent seven years with Sanofi-Synthelabo Inc. Mr. Welch graduated with honors from the University of Miami with a B.B.A. degree in Marketing. He also graduated from the University of North Carolina with an M.B.A. focused in Finance.

#### SAGE KELLY, UBS Warburg Global Healthcare Group

Sage N. Kelly joined UBS Warburg in March, 1999 and currently serves as a Director. Prior to joining UBS Warburg, Mr. Kelly was employed by Salomon Smith Barney from 1994 in the Health Care Investment Banking Group. Prior to joining Salomon Smith Barney, Mr. Kelly spent three years working in the Biotechnology industry for Genetics Institute.

# Heller Ehrman The System

After forty years of helping revolutionize the Life Sciences, Heller Ehrman is renowned for navigating complex legal, financial and regulatory roadblocks. But challenging systems means more than grasping the central nervous system of law. It means keeping our finger on the pulse of science and having infinite respect for the challenges of improving and prolonging human life.



## **Breakout Session Panelists**

#### RODNEY D. ALTMAN, M.D., Partner, TVM Management

Dr. Altman is a partner with TVM Management, a venture capital firm with an international team operating out of Germany and the U.S. His interests include pharmaceuticals and therapeutics, medical devices, and healthcare information technology. Prior to joining TVM, he was the Assistant Medical Director of the emergency department of MacNeal Hospital in suburban Chicago. Dr. Altman holds a medical degree from McGill University; completed his residency at the University of Illinois at Chicago; and obtained his M.B.A. with Honors from the University of Chicago.

#### ANTOINETTE AZEVEDO, President and CEO, e-SubmissionsSolutions.com

e-SubmissionsSolutions.com (a California corporation) was founded by Antoinette Azevedo in 2000 to advise all sizes of biotechnology and pharmaceutical companies on the use of technology to manage regulatory documents and publish electronic submissions. Ms. Azevedo's clients range from large, international pharmaceutical companies to small, virtual west coast biotechnology companies—all attempting to be better prepared to manage controlled documents and produce electronic drug registrations. Her entire career has been devoted to document management and electronic publishing through a number of generations of technologies and architectures.

#### FLOYD E. BLOOM, M.D., Chief Executive Officer, Neurome, Inc.

Dr. Bloom is the immediate past Editor-in-Chief of Science, the world's premier journal of scientific thought and discovery, and is the Chairman of the Department of Neuropharmacology at The Scripps Research Institute in La Jolla. A member of the National Academy of Sciences since 1977, he is the recipient of numerous prizes for his contributions to science, including the Janssen Award in the Basic Sciences and the Pasarow Award in Neuropsychiatry. He has also been named a member of the Royal Swedish Academy of Sciences and a member of the National Academy of Medicine. Dr. Bloom's more than 600 publications include the seminal work: The Molecular Basis of Neuropharmacology.



#### KATHERINE S. BOWDISH, Ph.D., President, Alexion Antibody Technologies, Inc.

Dr. Katherine Bowdish is currently President of Alexion Antibody Technologies, Inc. and Senior Vice President of Alexion Pharmaceuticals, Inc. subsequent to the September 2000 merger of Prolifaron, Inc. with Alexion Pharmaceuticals. She was previously founder, Chief Executive Officer, and Chief Scientific Officer of Prolifaron, Inc., a San Diego, CA based antibody engineering company. Under Dr. Bowdish's leadership, Prolifaron emerged as an innovating leader in the generation of combinatorial human antibody therapies for treatment of cancer, autoimmune disorders, and infectious diseases.

#### LESLIE J. BROWNE, Ph.D., Chief Operating Officer, Iconix Pharmaceuticals, Inc.


Dr. Browne is responsible for all research, development and informatics activities at Iconix Pharmaceuticals, Inc. Prior to joining Iconix, Dr. Browne spent over a decade at Berlux/Schering AG, most recently as Corporate Vice President, Berlux Laboratories, Inc. and President of Schering Berlin Venture Corporation. He also served as Vice President, Head of Discovery Research at Berlex Biosciences, where he established the drug discovery operations. Dr. Browne received his Ph.D. from the University of Michigan and was an N.I.H. postdoctoral fellow at Harvard University with the Nobel Laureate, Professor R.B. Woodward.

#### ROY E. S. BULLINGHAM, M.D., Vice President, Pharmacia Corporation

After studying organic chemistry in Cambridge, Roy Bullingham qualified in medicine and anesthesiology in the UK. After five years in academic clinical pharmacology research on analgesics, he joined Syntex in 1983. He has worked in various therapeutic areas, in all development phases, in Europe and the U.S. Presently he is Vice President of Global Clinical Pharmacology for Pharmacia, based in New Jeresey. Current interests are in the early development phases and the applications of pharmacogenomics.

# LIFE SCIENCES Leadership

Who do the nation's leading biotech, medical device and



18 CALBIOsummit 2002

#### JOHN CHIPLIN, Ph.D., President and CEO, GeneFormatics, Inc.

Dr. Chiplin, President, Chief Executive Officer and co-founder of GeneFormatics, has worked for a number of early stage bio-infotech companies that went on to become successful, multinational, profitable companies including Molecular Design Limited and Biosym Technologies, Inc. Immediately prior to co-founding GeneFormatics, Dr. Chiplin was Chief Executive Officer of Superscape p1c, one of the world's leading virtual reality technology companies, quoted on the London Stock Exchange. Born in 1958, he holds a B.S. in pharmacy and a Ph.D. in biochemistry from the University of Nottingham, England. Professional affiliations include memberships in the Pharmaceutical Society, the Royal Society of Arts, and the Institute of Directors.

#### BASSIL I. DAHIYAT, Ph.D., President and CEO, Xencor

Dr. Dahiyat is co-founder of Xencor and co-inventor of the PDA technology. He has been CEO since incorporation of the company in August of 1997. Dr. Dahiyat manages the Company's research activities and directs an aggressive patent strategy for Xencor's technology platform and proprietary proteins. Dr. Dahiyat has co-authored numerous scientific papers in the fields of protein design and drug delivery and has received scientific awards from the American Chemical Society, the Controlled Release Society, the Protein Society and Caltech. Dr. Dahiyat holds a Ph.D. in Chemistry from Caltech and B.S. and M.S.E. degrees in Biomedical Engineering from the Johns Hopkins University.

#### SYDNEY G. EDWARDS, Ph.D., Principal, TL Ventures

Dr. Edwards is a Principal in TL Venture's Biotech practice, where he focuses on emerging biotechnology companies that develop therapeutic drugs, as well as spinoffs from large pharmaceutical companies. Previously, Dr. Edwards was a Senior Manager in Corporate Finance for Amgen, where he provided financial and strategic analyses for Amgen's Executive Committee and numerous teams. Prior to Amgen, Dr. Edwards was a Management consultant in Accenture's Pharmaceutical Practice. Dr. Edwards earned a Ph.D. degree in Biochemistry from Pennsylvania State University, and M.B.A. in Strategy and Finance from the MIT Sloan School of Management and a B.A. in Biochemistry from UC Berkeley.

#### JULIE A. ELLISON, Ph.D., Program Coordinator, Integrative Biology, Digital Gene Technologies, Inc.

Dr. Ellison is responsible for gene discovery using the TOGA<sup>™</sup> Technology and for characterization of gene function through the integration of cellular and anatomical techniques drawn from molecular genetics, cell biology, anatomy and histology. She directs the Neuroscience gene discovery effort through the development of animal and cell culture models to identify new diagnostic and therapeutics targets for neurological diseases. Prior to joining DGT, Dr. Ellison was an Assistant Professor in the Department of Neurosurgery at UCSF. She is a graduate of U.C. Berkeley, and received her Ph.D. from U.C. Los Angeles. Her postdoctoral training included a fellowship in the Department of Neuroscience, Children's Hospital, Harvard Medical School where she conducted research on cerebral palsy and postdoctoral training at SmithKline Beecham Pharmaceuticals where she conducted research on novel gene expression associated with ischemic brain injury. Dr. Ellison's research focus prior to joining DGT was the molecular and cellular mechanisms underlying tissue remodeling after CNS injury.

#### MAURICE S. EMMER, Partner, Deloitte & Touche LLP

Mr. Emmer is a partner in the International Tax practice of Deloitte & Touche. He serves as the leader of the firm's Global Earnings Mobility Strategies Practice, and, as such, he helps multinational enterprises identify and implement strategies for minimizing global taxation. His diverse client base includes a number of biotechnology and pharmaceutical companies as well as venture capital firms. Prior to joining Deloitte, Mr. Emmer practiced law with Baker & McKenzie's International Tax group for 23 years. He received his B.S. in Accounting from the Wharton School of Finance and Commerce at the University of Pennsylvania and his J.D. from the University of Chicago Law School.

#### STEPHEN C. FERRUOLO, Shareholder, Heller Ehrman White & McAuliffe LLP

Stephen Ferruolo joined Heller Ehrman White & McAuliffe LLP in 1993 and has a practice emphasizing corporate and securities law. Mr. Ferruolo currently co-chairs the firm's Life Sciences National Practice Group and serves on the firm's Policy Committee. Mr. Ferruolo has participated in a variety of public and private financings, acquisitions, joint ventures, strategic partnerships and technology licenses for life sciences and high-technology companies.

#### M. WAINWRIGHT FISHBURN, Jr., Partner, Cooley Godward LLP

M. Wainwright Fishburn, Jr. is a partner in the firm's Business Department and is a resident in the San Diego office. Mr. Fishburn's practice emphasizes general representation of high growth technology and other operating companies that range from start-ups to publicly held corporations. His practice focuses on corporate governance matters as well as mergers, acquisitions, strategic alliances, and intellectual property licensing and management. He also assists his client companies in financing matters, often involving the placement of debt and equity securities. Mr. Fishburn joined the firm in June 1992 as a founding partner in the San Diego office.

#### J. GORDON FOULKES, Ph.D., Executive Vice President of Research & Development, Elitra Pharmaceuticals

Dr. Foulkes has served as the Executive Vice President of Research & Development and a member of the board of directors at Elitra Pharmaceuticals since January 1999. Prior to joining Elitra, Dr. Foulkes served as Chief Technical Officer of Aurora Biosciences Corporation, a biotechnology company, from 1996 to 1998, and Chief Scientific Officer of Oncogene Science, Inc., a biotechnology company, from 1987 to 1996. Dr. Foulkes holds a Ph.D. from the University of Dundee in Scotland where he studied with Professor Sir Philip Cohen.

#### ANTHONY W. FOX, M.D., Ph.D., FFPM, FIBiol, President, EBD Group

Originally from The Royal London Hospital, Dr. Fox was also a Fellow at Emory University and Harvard. Industrial positions have included Proctor and Gamble, Glaxo Inc., and two small companies. Dr. Fox is a Vice President of the American Academy of Pharmaceutical Physicians, and a Fellow of the Faculty of Pharmaceutical Medicine (Royal Colleges of Physicians, UK). Publication areas include: regulation, pharmacology, clinical trials, pharmacovigilance, analgesics, migraine, genotoxicology, and metabalism, plus four patents. Five journals use his reviews.

#### DORA GAMES, Ph.D., Principal Scientist, Elan Pharmaceuticals

Dr. Games has focused on developing animal models and therapeutic approaches for neurodegenerative diseases during the last 14 years as a scientist in the life sciences industry. She is a Senior Scientist at Elan Pharmaceuticals, where she continues her work on Alzheimer's Disease (AD) therapeutics, previously established at Athena Neurosciences. She and her colleagues characterized the PDAPP transgenic mouse model of AD pathology, currently being used to develop novel therapeutics for AD.

#### LUTZ B. GIEBEL, Ph.D., President and CEO, CyThera, Inc.

Dr. Giebel is President, CEO and Founder of CyThera, Inc., a recently formed company in the field of cell therapy and regenerative medicine, with an initial focus on the development of functional islet cell transplants for the treatment of insulin-dependent diabetes. CyThera is one of the only 11 organizations included in the NIH Registry as an approved source of human embryonic stem cell lines for federally funded biomedical research. Prior to founding CyThera, Inc., Dr. Giebel was founder and Vice President of R&D at MetaXen, and he has held various management positions, including Senior Director of Molecular Biology at Arris Pharmaceuticals, now Celera Genomics Group.

#### **MICHAEL GREY, Chief Business Officer, Structural GenomiX**

Mr. Grey is the Chief Business Officer of SGX. Between 1999 and 2001, Mr. Grey served as President and Chief Executive Officer of Trega Biosciences, Inc. until its acquisition by Lion Bioscience. Prior to joining Trega, Mr. Grey was President of BioChem Therapeutics, Inc., a subsidiary of BioChem Pharma, Inc., from November 1994 to August 1998. in 1994, Mr. Grey was the President and Chief Operating Officer for Ansan, Inc. Mr. Grey serves on the Board of Directors of both Cortex Pharmaceuticals, Inc. and Epimmune, Inc.

#### DANIEL P. GOLD, Ph.D., Executive Vice President, Favrille, Inc.

Dr. Gold is co-Founder and Executive Vice President of Research and Development of Favrille, Inc. Dr. Gold holds an adjunct appointment as an Associate Professor at the Sidney Kimmel Cancer Center where, prior to joining Favrille, he was laboratory director of the Cancer Immunogene Therapy program. Dr. Gold has been involved in multiple phase I/II clinical trials for indications including non-Hodgkin's lymphoma, B cell lymphoma, colorectal carcinoma, prostate cancer and multiple sclerosis.

#### LAWRENCE S. B. GOLDSTEIN, Ph.D., Professor of Cellular and Molecular Medicine, University of California, San Diego

Dr. Goldstein is an Investigator with the Howard Hughes Medical Institute and a Professor in the Department of Pharmacology and the Department of Cellular and Molecular Medicine at the University of California School of Medicine, San Diego. He received his B.A. degree in biology and genetics at UCSD, his Ph.D. degree in genetics from the University of Washington, Seattle, and did postdoctoral work at the University of Colorado, Boulder, with Richard McIntosh, and at the Massachusetts Institute of Technology. Prior to moving to UCSD, Dr. Goldstein was Professor of Cellular and Developmental Biology at Harvard University.

#### JEFFREY A. GREEN, Pharm.D., President and Chief Executive Officer, DATATRAK International, Inc.

Dr. Green has over 20 years of experience in clinical drug development both within the academic and corporate environments. From 1982-1992, he developed an independent clinical research program while a faculty member in the Division of Cardiology/Radiology at Case Western Reserve University/University Hospitals of Cleveland. While directing this program, Dr. Green served as an investigator on more than 90 individual investigations in the cardiovascular and imaging (PET scanning) subspecialty areas. Dr. Green founded DATATRAK, Inc. and initiated its strategy in the emerging Electronic Data Capture (EDC) arena.

#### DONALD W. GRIMM, Venture Partner, HamiltonApex Technology Ventures

Mr. Grimm has had a distinguished career with Eli Lilly and Company. His career spanned both the pharmaceutical business at Lilly as well as the biotechnology and medical device businesses. He held various pharmaceutical management positions with Lilly including Director of Worldwide Pharmaceutical Pricing, Director of Pharmaceutical Market Research, and Director of Sales for the pharmaceutical business on the West Coast. Following these assignments, Mr. Grimm was President, CEO and Chairman of Hybritech, Inc. While Grimm was at Hybritech, he orchestrated the development of Prostate Specific Antigen (PSA), the most significant new cancer diagnostic test ever developed for men. Hybritech went from \$50 million to \$150 million in revenues under Grimm's leadership.

## While you navigate the science we steer you through the legal landscape

Chiron Cerus Raven Targeted Genetics Viventia Peptech Nugen La Jolla Pharmaceuticals Dynavax Toshiba America Biocardia Mendel NeoRx Vistagen Millenium Peptech (Australia) Titan Pharmaceuticals Medicis Galileo Apollo Mergen Arcturus University of California Stanford University



CALBIOsummit 2002 21

#### DAVID F. HALE, President and CEO, CancerVax Corporation

David Hale is President and CEO of CancerVax Corporation, a biotechnology company involved in the development of biological products for the treatment of cancer. Mr. Hale has been involved in the biotechnology industry since joining Hybritech, Inc. in 1982. He became Chief Operating Officer in late 1982, President in 1983 and CEO in 1986, when Hybritech was acquired by Lilly. He was Chairman and CEO of Gensia from 1987 to 1997 and Chairman of Viagene, Inc. from 1987 to 1994, when Viagene was acquired by Chiron. He was President and CEO of Women First HealthCare from 1987 to June 2000. Prior to joining Hybritech, he held marketing and sales positions with Johnson & Johnson and Becton Dickinson.

#### NABIL HANNA, Ph.D., Chief Scientific Officer/Senior VP, IDEC Pharmaceuticals Corporation

Dr. Hanna joined IDEC Pharmaceuticals in 1990. During his tenure, Dr. Hanna was involved in the discovery and development of Rituxan and Zevalin, two FDA approved antibodies for NHL therapy. From 1981 to 1990, Dr. Hanna served as Director of Immunology at SmithKline Beecham focusing on autoimmune diseases. From 1978 to 1981, he was a research scientist at the NCI-FCRC, studying the role of NK cells in host defenses against cancer metastasis.

#### CARLOS D. HEREDIA; Partner, Morrison & Foerster, LLP

Carlos D. Heredia is a partner in the San Diego office of Morrison & Foerster. His practice includes public and private offerings, mergers and acquisitions and technology licensing. Mr. Heredia received his J.D./M.B.A. from Stanford Law School and Stanford Graduate School of Business. He serves as Co-President of the San Diego Chapter of the Stanford GSB Alumni Association. Mr. Heredia began his professional career with Allergan Inc., a specialty pharmaceutical company located in Irvine, California.

# A pipeline of innovation, the front line of a revolution.

At Celgene's Signal Research Division, we're innovating life. We're identifying new classes of small molecules that selectively regulate disease-associated genes. And we're using our advanced target-to-drug capabilities to build a diverse portfolio of drug candidates for cancer and immunological diseases. Other



companies have yet to find a way to join the post-genomic drug discovery revolution; the Signal Research Division is a big part of why Celgene is helping to lead it.

#### WWW.CELGENE.COM

888.4.CELGENE (888.423.5436)

#### EDWARD W. HOLMES, M.D., Vice Chancellor for Health Sciences and Dean of the School of Medicine, University of California, San Diego

In the fall of 2000, Dr. Holmes was appointed Vice Chancellor for Health Sciences and Dean of the School of Medicine at the University of California in San Diego. A graduate of the University of Pennsylvania Medical School, Dr. Holmes pursued a highly successful academic career with leadership positions at Duke, University of Pennsylvania, and Stanford, where he was Vice President for Translational Medicine and Clinical Research and Special Counselor to the President on Biomedical Research. Dr. Holmes is currently active on the NIH Scientific Boundaries Panel, the Scientific Advisory Board of SmithKline Beecham, and the NIH National Diabetes and Digestive and Kidney Diseases Advisory Council.

#### BRUCE A. HUEBNER, Executive Vice President and Chief Operating Officer, Gen-Probe, Inc.

Mr. Huebner has been in the medical diagnostics/biotech field for the past 28 years. His experience includes various roles in sales and marketing with Roche Diagnostics, the Director of Marketing role for the U.S. and then for Europe with Hybritech, and Vice President of Marketing and Sales for Quidel. He has been with Gen-Probe for the past 9 1/2 years, of which the past 6 years has been as Executive Vice President and COO. His current responsibilities include managing R&D, Sales and Marketing, Corporate Development, and Program Management, including strategic planning and the execution of these plans in order to achieve Gen-Probe's corporate P&L objectives.

#### RICHARD A. KAUFMAN, Shareholder, Heller Ehrman White & McAuliffe LLP

Richard A. Kaufman is a shareholder and a member of the Life Sciences and Information Technology National Practice Groups at Heller Ehrman White & McAuliffe LLP. Mr. Kaufman specializes in a wide variety of corporate and securities transactions for companies in the life sciences industry including developers of drugs, biologics, medical devices, and discovery and informatics tools. His practice includes structuring and negotiation of strategic partnerships and collaborations, technology transfers and licenses, spin-outs, manufacturing agreements, and clinical research agreements, as well as engagements for public offerings, private placements, mergers, acquisitions and divestitures. He has served as a General Counsel for three publicly held life science companies.

#### S. WAYNE KAY, President & CEO, Quidel Corporation

Mr. Kay joined Quidel as President & COO in January 2001. Quidel is a leading provider (manufacturer) of rapid, point-of-care diagnostic products for the healthcare professional and consumers worldwide. The Company is the market share leader of professional pregnancy and Strep A diagnostic test kits and produces a full breadth of products used in healthcare points-of-care. Wayne was appointed the President & CEO in August 2001. Prior to joining Quidel, Wayne led market and supply chain development and supplier management activities for Neoforma.com. Mr. Kay completed undergraduate studies in microbiology and business administration at Virginia Tech and the University of San Francisco and received an M.B.A. in management from Pepperdine University.

#### BERNARD D. KING, M.D., M.B.A., Principal, Macnas Consulting International

Macnas Consulting International specializes in strategic product development planning and execution for pharmaceutical, biotechnology and medical device companies and in due diligence consulting for venture capital, investment, and pharmaceutical firms. Dr. King's breadth and depth of experience are particularly valuable to smaller companies facing significant strategic product development decisions. Dr. King has over 15 years experience managing business and development operations and has held senior management and development positions at: Predict, Inc., PAREXEL, Advanced Bioresearch Associates, Trega Biosciences, Advanced Tissue Sciences, ConvaTec, a BristolMyers Squibb subsidiary, and SmithKline. Dr. King has a B.S. (Notre Dame) and M.D. (Ohio State). He is Board certified in Cardiology and Internal Medicine. He received his M.B.A. from the Wharton School of the University of Pennsylvania.

#### JEFFREY KLOFFT, Vice President and General Manager of Data Management Products, Phase Forward Incorporate

Mr. Klofft helped found Phase Forward Incorporate in 1997. Phase Forward is the clinical and safety informatics platform for research and development. Mr. Klofft brings to Phase Forward more than 15 years of experience in the definition, development, delivery and support of software products. Most recently, Mr. Klofft was the Vice President of Product Development and Chief Technology Officer of Banyan Systems, where he oversaw the transition from proprietary network solutions to standards-based, Intranet solutions. Mr. Klofft holds a B.S.C.S. and M.S.C.S. from Worcester Polytechnic Institute.

#### DANA KOPPER, CIC, ARM, Senior Vice President, Marsh USA Inc.

Mr. Kopper is a Senior Vice President with Marsh USA Inc., and the FINPRO (Financial and Professional Services Group) Practice Leader for the Newport Beach and San Diego offices of Marsh Risk and Insurance Services, part of the MMC (Marsh & McLennan Companies) family of companies. Mr. Kopper has provided a broad range of governance and risk management consulting / transactional services to public, private, for-profit, and not-for-profit organizations for the past 24 years – the past 12 years with Marsh. From a transactional perspective, he is one of the top D&O brokers in the country, having structured more than 2,500 D&O insurance and risk financing programs.

#### JOHN W. KOZARICH, Ph.D., President, CEO and CSO, ActivX Biosciences

Dr. Kozarich is currently President, CEO and Chief Scientific Officer of ActivX Biosciences, a new proteomics company based in La Jolla, CA. He received a Ph.D. in 1975 from MIT (Biological Chemistry). He has been a Professor of Pharmacology at Yale University School of Medicine, Professor of Chemistry and Biology at the University of Maryland, Vice President for Research and Development at Alkermes, and Vice President of Biochemistry at Merck Research Laboratories.

#### JANICE H. KURTH, M.D., Ph.D., Independent Consultant

Dr. Kurth earned her Ph.D. in human genetics at Stanford University, and her M.D. from the University of Arizona, with post-graduate training in internal medicine. After an academic research career, Dr. Kurth has held positions as Director of Pharmacogenetics for Sequana Therapeutics, Genset Corporation and Phenogenex, and Vice President of Genomics for Pharsight Corporation. She currently is an independent consultant performing technology assessment, strategic and product planning, and research management in the fields of human genetics and pharmacogenetics.

#### ROBERT LEACH, Ph.D., President and Chief Operating Officer, Tenex Greenhouse Ventures

Robert Leach is the President, Chief Operating Officer, and a Managing Partner of Tenex Greenhouse Ventures. He is responsible for smooth running the Greenhouse fund, ensuring that deals are well represented and that there is sufficient deal flow. Mr. Leach served as Chairman and CEO of EPIcyte Pharmaceutical. He completed an angel financing followed by the Company's first venture capital round. He also completed a strategic alliance with Dow Chemical providing some \$50 million of value to the Company. Mr. Leach has an M.B.A. and a B.S. from Pennsylvania State University.

#### ANTHONY F. MAIDA, President and Chief Executive Officer, Replicon Technologies, Inc.

Mr. Maida is the President and CEO of Replicon Technologies, a biopharmaceutical company developing therapeutic applications of replicons for human tumors. Mr. Maida also is Acting CEO of Trellis Bioscience, a visual proteomics company, where he was responsible for securing Trellis' first round of financing. Mr. Maida also is Chairman of BioConsul Drug Development Corporation. Mr. Maida previously served as Interim President of CancerVax, where he was responsible for securing \$30 million in financing, and as President and CEO of Jenner Biotherapies.

#### ROBERT W. OVERELL, Ph.D., General Partner, Frazier & Company

Dr. Robert Overell is a general partner with Frazier Healthcare Ventures, a leading life science venture capital firm based in Seattle with more than \$750M under management. He focuses primarily on company formation and seed/early stage venture investing in the biotechnology sector. He has played a key role in the founding and/or growth of several successful early stage biotechnology companies, including ActivX, Inc., Array BioPharma, Inc. and XenoPort, Inc. He obtained his Ph.D. from the Institute of Cancer Research, University of London, UK. Dr. Overell joined Frazier & Company in 1996 and currently serves on the boards of ActivX, Inc., Array BioPharma, Inc., GeneMachines, Inc., QuantumDot Corporation, and XenoPort, Inc.

#### DAVID NASSIF, B.Sc., J.D., Principal, Strategic Consulting Services

Mr. Nassif holds honors finance and law degrees from the University of Virginia and practiced corporate law before moving into business in 1987. Since then he has functioned as the Chief Financial Officer of 4 companies and has more than 7 years of experience as a Chief Financial Officer in the life sciences industry. He has negotiated more than 60 clinical trial agreements during that time. He is currently a principal with Strategic Consulting Services of Carlsbad, California, which offers a variety of high-level advisory services to biotech, medical device, diagnostic and high-tech companies at all stages from formation to those that are publicly held.

#### TINA S. NOVA, Ph.D., Chief Executive Officer, President and Co-Founder, Genoptix, Inc.

Dr. Nova is Chief Executive Officer, Co-Founder and a Director of Genoptix, Inc. Over the past several years she has been involved in the co-founding of three life science companies in the San Diego biotechnology community. Her current company, Genoptix, Inc., a venture-backed biotechnology company, is developing advanced cellular characterization techniques applicable in the post-genomics area. She received a B.Sc. degree in Biological Sciences at the University of California, Irvine, where she graduated with Honors, and she received her Ph.D. in Biochemistry from the University of California, Riverside.

#### LARRY R. PILOT, Partner, Washington, D.C., McKenna & Cuneo, LLP

Larry Pilot joined McKenna & Cuneo's Washington, D.C. office in 1983 and currently chairs the firm's Food and Drug Department. Mr. Pilot has been involved in the practice of food and drug law for thirty years and is recognized as an authority on legal issues relating to the development, manufacture, and distribution of medical devices. He is a registered pharmacist and a frequent speaker and author on the law relating to medical devices.

RADHIKA RAO, J.D., Professor of Law; Member, California Human Cloning Advisory Committee, University of California Hastings College of the Law Born in India, Professor Rao grew up in Lexington, Massachusetts, and attended Harvard College where she studied physics and chemistry. She later returned to graduate magna cum laude from Harvard Law School. Professor Rao teaches and writes in the areas of constitutional law, family law, property, and law and medicine. She has testified before various governmental bodies on the subjects of genetic screening, human cloning, and the constitutionality of proposed laws regulating assisted reproduction and late-term abortions. In 1999, she was appointed to the California Advisory Committee on Human Cloning, a 12-member commission established to study the issue and to provide advice regarding possible legislation.




# BUILDING FOR THE FUTURE

Rudolph and Sletten is a leader in the West Coast construction industry with over 40 years of general contracting experience. We specialize in the following market segments:

- Biotech
- Pharmaceutical
- Corporate Campuses Data Centers • High-Tech
  - Health Care
- Institutional
- Tenant Improvements
- Entertainment

For more information on Rudolph and Sletten, please contact Bob Maxwell at (858) 455-1161 or bob\_maxwell@rsconst.com



#### RALPH A. REISFELD, Ph.D., Professor, Dept. of Immunology, The Scripps Research Institute

Dr. Reisfeld is a Professor at The Scripps Research Institute since 1970, with his research focusing on cancer immunotherapy with DNA vaccines and immunocytokines. His former employment was at NIH where he worked as a Section Chief of Immunogenetics in transplantation immunology from 1963 to 1970. Prior to this, he was employed as a Group Leader at Merck, Sharp & Dohme (1959 to 1963) and as a Research Chemist at NIH where he worked in endocrine biochemistry from 1957-1959.

#### JEFFERY L. RILEY, Vice President, Strategy and Corporate Development, Ontogen Corporation

Mr. Riley joined Ontogen in June 2001. He was most recently the Chief Operating Officer at AvMax, Inc., a San Francisco-based biotech company. Prior to this position, he served in a variety of management roles in Europe and Latin America for such notable companies as Nichols Institute (A Division of Quest Diagnostics, Inc.), Pfizer Pharmaceuticals, Inc., SmithKline Beecham Plc. and Citibank-Brazil. Mr. Riley holds a B.S. in International Relations/Biology and participated in a dual-degree graduate program sponsored by Arizona State University and American Graduate School of International Management (Thunderbird), earning a Master of International Management (M.I.N.) and an M.B.A.

#### DARREN J. ROBBINS, Partner, Milberg Weiss Bershad Hynes & Lerach LLP

Darren J. Robbins was admitted to the California bar in 1993. He was admitted to practice before the U.S. District Court for the Northern and Southern Districts of California in 1994 and to the Central District in 1998. Mr. Robbins received a M.A./B.S. from the University of Southern California in 1990 and a J.D. from Vanderbilt University in 1993. He was a member (1991-1992) and Managing Editor (1992-1993) of the Vanderbilt Journal of Transnational Law.

# Zevalin<sup>™</sup> (Ibritumomab tiuxetan) is now approved! First in radioimmunotherapy

For more information about Zevalin, visit our Web site at www.zevalin.com

# ZEVALIN<sup>™</sup> Ibritumomab tiuxetan

Precise targeting. Proven antibody. Potent isotope.



©2002 IDEC Pharmaceuticals Corporat All rights reserved Printed in USA. 106-053 April 2002.

#### DIANE J. ROMZA-KUTZ, J.D., L.L.M., Partner, Mayer, Brown, Rowe & Maw

Diane J. Romza-Kutz, Partner in the Health Care Biotech/Pharma Practice at Mayer, Brown, Rowe & Maw, advises U.S., European and Canadian pharma, biotech and medical device companies on regulatory and compliance issues, including approval processes, marketing and promotion issues, enforcement matters and clinical trial agreements and related issues, such as interacting with IRBs informed consents. She also provides corporate compliance advice to pharma and biotech companies.

#### IVOR ROYSTON, M.D., Managing Member, Forward Ventures

Dr. Royston is currently a Managing Member and co-founder of Forward Ventures and a nationally recognized oncologist and cancer immunologist. Dr. Royston was a founder of Hybritech, IDEC Pharmaceuticals, GenStar Therapeutics, and the Sidney Kimmel Cancer Center (SKCC). Dr. Royston received his B.A. and M.D. degrees from John Hopkins University and post-doctoral training in internal medicine and medical oncology at Stanford University. He served as Director of Clinical Immunology at the UCSD Cancer Center (1977-1990), President of SKCC (1991-2000), and Presidential appointee to the National Cancer Advisory Board (1996-2002).

#### LYNN RUBENSON, Senior Vice President, Biotech and Healthcare Practice, Fleishman Hillard/San Diego

Lynn Rubenson offers more than 20 years of experience developing and leading communications programs for consumer products and healthcare services. She recently joined Fleishman Hilliard's office in San Diego to lead the healthcare and biotechnology practice as well as the consumer marketing group. The healthcare clients that she oversees include Lignan Research, which specializes in research, development, and manufacture of novel lignan-based phytochemicals for medicinal over-the-counter application. In addition, she manages the Susan G. Komen Race for the Cure/San Diego account team.

#### TONI SCHUH, Ph.D., President, Chief Executive Officer, SEQUENOM, Inc.

Dr. Schuh was appointed as SEQUENOM's President and CEO and as a member of its Board of Directors in May 2000. He has been a member of SEQUENOM's executive team since 1996 and played a leading role in developing SEQUENOM's business strategy and in the development of commercial and strategic partnerships. Before joining SEQUENOM, he was the Head of the Pharma Business Development Group at Helm AG. He holds a Ph.D. in pharmaceutical chemistry from the University of Bonn, Germany.

#### DAVID SHAPIRO, M.D., Executive Vice President and Chief Medical Officer, Idun Pharmaceuticals, Inc.

Dr. Shapiro trained in Medicine at the University of Dundee and, as a postgraduate at the University of Oxford's hospitals and the University of Vermont. In 1985 he joined Merck and since then gained experience in virtually all segments in clinical drug development with positions at Gensia, Scripps Clinic and as head of a consulting company. He currently serves as EVP and Chief Medical Officer for Idun. He is active in professional development and has organized and chaired several international symposia.

#### DAVID M. SHEEHAN, President of Digirad Imaging Solutions, Digirad Corporation

Prior to joining Digirad in September 2000, Mr. Sheehan was the President and CEO of Rapidcare.com, an e-health company that connects physicians with families and children who suffer from chronic disease. Previously, Mr. Sheehan was the Vice President of Sales & Marketing for Baxter Perfusion Services for two years. Prior to Baxter, he worked for approximately six years with Haemonetics Corporation, the leading supplier of blood processing equipment and services, in various sales, marketing, and business development positions. Mr. Sheehan earned a B.S. in Mechanical Engineering from Worcester Polytechnic Institute and an M.B.A. from the Tuck School of Business at Dartmouth College.

Paul A. Stewart is a partner in the San Francisco office of Foley & Lardner. He is California Vice Chair of the Business Department and Chair of the Health Technology Practice Group. Mr. Stewart's practice emphasizes business, technology, and corporate matters. Mr. Stewart has served as chief legal counsel for numerous private companies, ranging from start-ups to established organizations active in technology, consulting, financing, retailing, health care, real estate and other sectors. Mr. Stewart is a Phi Beta Kappa graduate of Stanford University (B.A., 1969) and Yale Law School (J.D., 1972). He was admitted to the California Bar in 1972.

#### HARRY STYLLI, Ph.D., President, Aurora Biosciences Corporation

Dr. Harry Stylli currently serves as President of Aurora Biosciences Corporation, a wholly owned subsidiary of Vertex Pharmaceuticals. Prior to his appointment as President, Dr. Stylli held the position of Senior Vice President of Commercial Development where he was responsible for business development marketing and sales, and new ventures from May 1999 to July 2001. Previously, Dr. Stylli was Senior Vice President of Screen Technology and New Ventures and was responsible for development and manufacture of Aurora's ultra-high throughput screening system, miniaturization technologies and new business opportunities. Dr. Stylli joined Aurora in November 1995 as one of the founders and co-author of the business plan.

#### FRANK TUFARO, Ph.D., Managing Director, Medigene, Inc.

Dr. Frank Tufaro is an international leader in the field of molecular virology, specializing in the biology and genetics of herpes viruses and their development and testing for gene therapy. Dr. Tufaro founded NeuroVir Therapeutics in 1996 to develop herpes simplex virus vectors for use as cancer therapeutics against a wide range of tumor cells including those resistant to chemotherapy and radiation. In 2001, NeuroVir Therapeutics was acquired by MediGene, Inc., a German-based biopharmaceutical company specializing in cardiology and oncology. Dr. Tufaro currently serves as the Executive Vice President and Managing Director of MediGene, Inc.

#### SOPHIA TWADDELL, Senior Vice President and Partner, Biotechnology Practice Leader, Fleishman Hilliard/Chicago

Sophia Twaddell is a seasoned senior counselor with 23 years of healthcare communications experience, both in corporate and agency settings. She has expertise in a broad range of therapeutic categories, from cardiovascular to cough and cold, and has developed strategic advertising and public relations programs for biotechnology, diagnostic, hospital supply, medical device, nutrition, and pharmaceutical products. Ms. Twaddell is senior vice president and partner in the Chicago office of Fleishman Hilliard and director of FH's biotechnology practice. Under her leadership, the practice has carved out a unique niche: counseling life sciences companies around corporate reputation and financial communications as well as around traditional, brand-related public relations.

#### MICHAEL V. WARD, D.V.M., Vice President, Clinical Affairs, Provasis Therapeutics, Inc.

Born, raised and educated in Canada, Dr. Ward received a Doctor of Veterinary Medicine from the Ontario Veterinary College, Guelph, Ontario. Dr. Ward has an extensive research background in cardiovascular and neurovascular diseases as well as in hemostasis/thrombosis that spans positions in both academia (Wake Forest Medical School) and industry. Over 12 years was spent with several divisions in Baxter Healthcare Corporation. Other industry positions were with Aprex Corporation, Target Therapeutics (Boston Scientific) and W.L. Gore.

#### TOSHIFUMI WATANABE, Ph.D., President and CEO, Takeda Research Investment, Inc.

Dr. Watanabe leads Takeda Research Investment, Inc., a division of Takeda Pharmaceuticals N.A., founded to take advantage of Takeda Chemical Industries' growing international pharmaceutical business. Dr. Watanabe's extensive academic and professional experiences include the development of R&D strategies for cardiovascular and atherosclerosis drugs. He has provided strategic consulting and forged a number of alliances in the pharmaceutical industry. Dr. Watanabe received his B.Sc. and M.Sc. in Engineering from Nagoya Institute of Technology in Nagoya, Japan, and he earned his Ph.D. in Physiology and Biophysics from Dalhousie University in Halifax, Nova Scotia.

#### SHIRLI FABBRI WEISS, Partner, Litigation, Gray Cary Ware & Freidenrich LLP

Shirli Weiss has 22 years of experience defending companies, directors and officers and underwriters in class action litigation, including securities, anti-trust and consumer class actions, litigation arising from mergers and acquisitions and derivative litigation. Her practice includes the defense of underwriters and securities brokerage firms in litigation and arbitration; and resolution of insurance issues Arbitration before National Association of Securities Dealers, Inc., New York Stock Exchange, Inc., American Arbitration Association and National Futures Association with emphasis on representing companies and individuals in class action litigation and representing law firms in professional liability litigation.

#### ADAM WERNER, Ph.D., Senior Consultant, NERA Economic Consulting

Dr. Werner provides litigation support related to securities and finance. In addition to focusing on valuations and the use of options in damage estimates, Dr. Werner specializes in securities class actions where he has managed numerous cases. In the course of managing these cases, he has performed analyses involving issues of liability, class certification, market efficiency, materiality, affected trading volume, and damage calculations. In addition, while at NERA, he has lectured extensively on trends in securities class action suits. Prior to joining NERA, Dr. Werner was an Associate at a litigation consulting firm where he worked in the areas of financial institutions and securities. Much of his work focused on damage estimation for S&Ls in their breach of contract cases (Winstar) against the United States Government.

#### V. RANDY WHITE, Ph.D., Chief Executive Officer, Nanogen, Inc.

Dr. White joined Nanogen as Chief Executive Officer in June 2001 and has been a director of Nanogen since April 2001. Since 1998, Dr. White has been Executive Vice President of Technical Operations and Research and Development at American Medical Laboratories, Inc. From 1992 to 1998, he was a consultant to a diverse group of diagnostic clinics including Unilab, Specialty Laboratories and California Community Clinics providing services relating to operational efficiency, systems and cost improvement. From1985 to 1992, he was Executive Vice President, Operations for National Health Laboratories, Inc. and for the prior ten years served in various upper managerial and operations role with NHL. Dr. White received a B.S. and a Ph.D. in Chemistry from the University of Houston and completed post-doctoral training in clinical chemistry in Birmingham, AL.

#### KENNETH J. WIDDER, M.D., General Partner, Windamere Venture Partners, LLC

Dr. Widder is the founder and former Chairman/CEO of Molecular Biosystems, Inc., a biomedical company specializing in a range of contrast agents for use with diagnostic ultrasound. Simultaneously, he held the position of Chairman and CEO of Syngene, Inc. from 1990 to 1993. Currently, Dr. Widder is Chairman of Santarus, Inc. and is the Managing Partner for Windamere Capital Partners. Dr. Widder is author and co-author of numerous scientific publications and is owner of 15 patents. He acquired his Bachelor's Degree from Carlton College and his Medical Degree from Northwestern University. Dr. Widder completed his residency in Pathology at Duke University Medical Center.

## LA JOLLA PHARMACEUTICAL COMPANY

La Jolla Pharmaceutical Company (Nasdaq: LJPC) is developing new disease-specific therapeutics for potentially life-threatening diseases such as

lupus and antibody-mediated thrombosis. The Company is using its patented Tolerance Technology® to target large markets with major unmet needs. LJP 394, its lead compound for treating lupus renal disease, is in a Phase III clinical trial, its candidate for antibody-mediated thrombosis, LJP 1082, is in a Phase I/II clinical trial.



LJP-394 9-020 CN Store @ 2-La Jolla Physics

#### CHRISTOPHER J. WINROW, Ph.D., Laboratory of Genetics, The Salk Institute for Biological Studies

Christopher Winrow joined the Salk Institute for Biological Studies in 1999 as a Canadian Institute of Health Research Post-Doctoral Fellow in Carrolee Barlow's laboratory. He received his B.Sc. in molecular biology in 1993 from McMaster University (Canada) and his Ph.D. in cell biology in 1999 from the University of Alberta (Canada). His current research focuses on applying mouse genetics and genomics platforms to understand human tumorigenesis and neurodegenerative diseases.

#### JOHN F. WOOD, M.B.A., RAC, Director, Regulatory Affairs, Amylin Pharmaceuticals, Inc.

John Wood has worked in biotechnology for the past 12 years, beginning in a biochemistry laboratory where he developed various in vivo, in vitro and cellular assays to screen for potential enzyme inhibitor drug candidates and also isolated and characterized mutant E. Coli strains selected for enzyme production. For the past 9 years, Mr. Wood has worked in Regulatory Affairs both within biotechnology companies and as a consultant within the industry. Mr. Wood graduated with a Bachelor of Arts degree in biology from UCSD, is Regulatory Affairs Certified through the Regulatory Affairs Professional Society and has a Masters in Business Administration from the University of Phoenix.

#### GERALD J. YAKATAN, Ph.D., President and CEO, AVANIR Pharmaceuticals

Dr. Yakatan has been the President and CEO of AVANIR Pharmaceuticals since March 1998 and was successful in obtaining FDA approval for the Company's lead product, Abreva, using the FDA appeals process. He is the former VP of Worldwide Product Development for Warner-Lambert and the founding CEO of Tanabe Research Laboratories, USA, Inc. Dr. Yakatan has published more than 60 papers in the areas of pharmacokinetics and biopharmaceuticals, analysis of drugs and drug stability.

# You make the discoveries. We'll create the buzz.

Make the world understand how important your discoveries really are. At Atkins + Associates, we address the unique needs of emerging life sciences companies like yours. Our strategic counsel and pragmatic programs build media and investor relationships -relationships that can help you build your business and extend your reach among



institutional and retail investors, pharmaceutical partners, venture capitalists and others.

Get the word out. Find out more about how Atkins + Associates can help you by visiting us at www.atkinsassociates.com.



10660 scripps ranch blvd, suite 100 • san diego, ca 92131 • (p) 858.860.0266 • (f) 858.860.0270 Please visit our website at www.atkinsassociates.com We are pleased to welcome two special International Delegations to CALBIOsummit. For more information on these groups please stop be their Booths in the Exhibit Hall.

#### **Frankfurt Bio Tech Alliance**

Frankfurt Bio Tech Alliance is the catalyst for the accelerated growth of the biotechnology sector in the FrankfurtRhineMain Region. It serves as a proactive interest group, in which ad hoc working groups formulate biotech projects that strive to promote Frankfurt as a biotech area on a national and international level in order to attract foreign direct investment. The Frankfurt Bio Tech Alliance features many small and medium sized biotech firms, venture capital firms, law firms as well as research and industry parks next to the Big Pharma of Frankfurt. Among these companies, the Frankfurt Economic Development GmbH in cooperation with the Technology Foundation Hesse have taken the lead role for the planning and coordination of biotech activities.

Frankfurt Bio Tech Alliance Members at CALBIOsummit 2002 include CPC; Future Capital AG; Infraserv Hoechst; Mayer, Brown, Rowe & Maw Gaedertz and Xzillion GmbH & Co. KG.

#### Exhibit Space: 304 and 306



#### Frankfurt Bio Tech Alliance

## Hannover Chamber of Industry and Commerce

In Niedersachen, Germany biotechnology is a growth industry. 170 biotechnology companies have successfully been established up to now. All branches of biotechnology are represented in Niedersachsen, with a special focus on red biotechnology. The research triangle Braunschweig-Göttingen-Hannover is the largest biotechnology center in Northern Germany and ranks third in Germany.

Members of the Hannover Chamber of Industry and Commerce at CALBIOsummit include: Artiss GmbH; BioRegioN; BioVisioN; MaxXconGmbH; BioMed Venture AG; and Consultant Bioinformatics.



CALBIOsummit 2002 31

# 

GLORING, MEASURANCE COMPANYAGES

# **Abbott Laboratories** *Quality Health Care Worldwide*

**One20ne** is our state-of-the-art global pharmaceutical outsourcing group.

Expertise includes:

## EXTENSIVE PARENTERAL MANUFACTURING EXPERIENCE

Abbott One2One is the world's largest full service parenteral contract manufacturer. One2One expertise is focused on parenterals.

## WORLD CLASS R&D

One2One draws on Abbott's vast R&D resources which include 8,000 scientific personnel and an annual investment of over \$1 billion.

## LONG-TERM COMMITMENT

Abbott views its relationship with you as an ongoing commitment that extends beyond any one project.

## **REGULATORY TRACK RECORD**

Abbott has taken hundreds of drugs through the ever-changing regulatory environment from IND to registration, preapproval inspection, and commercial approval.

## STATE-OF-THE-ART MANUFACTURING FACILITIES

Abbott has a network of manufacturing facilities around

the world — with extensive capabilities to meet any

production requirements.

## For more information, please contact Mary Lou Glotzbach at 847-935-0945.

Abbott Laboratories Hospital Products Division Abbott Park, IL 60064

32 CALBIOsummit 2002

## EXHIBITORS

| Company Name  | Booth # | Company Name  | Booth #  |
|---|---------|---|----------|
| Alexander X, Inc.                                   | 211     | Maxim Pharmaceuticals                               | 205      |
| Aztec Business Machines                             | 218     | Maybridge plc and Ryan Scientific                   | 509      |
| BIOCOM/san diego                                    | 418     | Mayer, Brown Rowe and Maw                           | 207      |
| Biologics Process Development, Inc.                 | 314     | Mentus  | 104      |
| Bio Objects, Inc.                                   | 112     | Morrison & Foerster, LLP                            | 315      |
| BioSpace, Inc.                                      | 515     | Network Appliance, Inc.                             | 508      |
| BioStruct   | 319     | Newbiotics, Inc.                                    | 409      |
| Biotechnology Industry Organization (BIO)           | 407     | Nitech, Inc.  | 122      |
| BioWorld Today                                      | 108     | Office Depot Business Services Division             | 220      |
| Brobeck, Phlegar, & Harrison                        | 504     | PR Newswire   | 223      |
| California Manufacturing Technology Center          | 208     | Prudential Cleanroom Services                       | 222      |
| California Technology Trade and Commerce Agency     | 408     | Research Facilities Design                          | 321      |
| Celgene   | 406     | Rudolph & Sletten                                   | 105      |
| Center for Commercialization of Advanced Technology | 209     | San Diego Metropolitan & Daily Business Report      | 120      |
| Chubb Group of Insurance Companies                  | 114     | San Diego Regional Economic Development Corporation | 311      |
| City of Oceanside/Oceanside Economic Development    | 107     | San Diego Regional Technology Alliance              | 109      |
| Comerica Bank                                       | 214     | SEQUENOM, Inc.                                      | 123      |
| Conduit Systems, Inc.                               | 511     | Shanks & Herbert                                    | 413      |
| Cooley Godward LLP                                  | 113     | Siegfried Ventures                                  | 412, 414 |
| Cromedica, Inc.                                     | 206     | SignOnSanDiego                                      | 213      |
| CropLife America                                    | 514     | Silicon Valley Bank                                 | 308      |
| Deloitte & Touche                                   | 505     | Simco Electronics                                   | 309      |
| Document Imaging Service Corporation                | 410     | Sun Microsystems                                    | 419      |
| DPR Construction                                    | 312     | Susan Atkins & Associates                           | 204      |
| Epicyte Pharmaceutical, Inc                         | 411     | Tatum CFO Partners LLP                              | 415      |
| Express Scripts-Specialty Distribution Services     | 513     | The T-Sector  | 507      |
| Fashion Furniture                                   | 318,320 | TransPerfect Translations                           | 110      |
| Foley & Lardner                                     | 512     | UCSD Extension Bioscience                           | 210      |
| Frankfurt Bio Tech Alliance                         | 304,306 | University Research Park                            | 215      |
| Genset Corporation                                  | 118     | Voit Commercial Brokerage                           | 212      |
| Graphics Lab Inc.                                   | 119     | VWR   | 221      |
| Gray Cary Ware & Freidenrich                        | 305-307 | Western Scientific, Inc.                            | 313      |
| Harlan  | 219     | * Exhibitor List as of March 27, 2002               |          |
| Heller Ehrman White & McAuliffe LLP                 | 404     |   |          |
| IBM Corporation                                     | 510     |   |          |
| Idun Pharmaceuticals                                | 506     |   |          |
| Inland Empire Economic Partnership                  | 115     | Exhibit Hall Hours                                  |          |
| Intecon Systems                                     | 121     | Monday, April 22 10:00am - 7:30pm                   |          |
| Isis Pharmaceuticals                                | 310     | Exhibit Hall Reception starts at 5:30pm.            | 6.13     |
| Kforce Scientific                                   | 111     |   |          |
| Knobbe Martens Olsen and Bear, LLP                  | 106     | Tuesday, April 23 7:30am - 11:30am                  |          |
| Marsh   | 405     |   |          |

## Essential Tools: Life Sciences

The right tools are critical to companies sculpting innovative technologies from bodies of advanced scientific knowledge. Cooley Godward, a law firm with more than 600 attorneys, is one of those essential tools. From clinical research to commercialization, we understand where science intersects with business. Each year we form, finance and establish partnerships for hundreds of leading companies. So, when you think about the tools your company has to use, remember: Expertise is essential.

**Cooley Godward. Essential.** 

Cooley Godward LLP

www.cooley.com


For more information, please contact Barbara Kosacz at bkosacz@cooley.com or 650/843-5000.

BROOMFIELD . KIRKLAND . MENLO PARK . PALO ALTO . RESTON . SAN DIEGO . SAN FRANCISCO

34 CALBIOsummit 2002

### EXHIBIT FLOOR PLAN


U



1



# 



Do you know what payors think about the biotech drug you're developing? Ask us.

We know what's top-of-mind for payors because our parent company manages the pharmacy benefit for over 15,000 of them. Call 1-866-470-1753. Visit booth 513.



# Advance your Career with BioSpace Career Expos

Life Sciences Career Expo at CALBIOsummit

April 22, 2002


San Diego Convention Center San Diego, California

Time: 11:00 AM - 4:00 PM

### **Attending Companies Include:**

Advanced Clinical Services, AlleCure, Allergan, Amgen, Anadys Pharmaceuticals, Antigenics, Aviron, Baxter BioScience, Bio-Rad Laboratories, Cell Genesys, Chemicon International, Chugai Biopharmaceuticals, Contact Singapore, Genoptix, Illumina, Invitrogen, Kforce Scientific, Lab Suppport, PAREXEL International, Merck Research Laboratories, Structural GenomiX, Yoh Scientific and more.

Research **Development** Clinical CRA's Manufacturing Chemistry **Process Development** QC QA Regulatory **Bioinformatics** Crystallography Finance Engineering **Project Management** and Much more!



For exhibiting companies, information and free resgistration visit: www.biospace.com

### IS YOUR INSURANCE AS SOPHISTICATED AS YOUR BUSINESS?

With more than 20 years of experience in the information technology industry, Chubb has become the property/casualty insurer of choice for over 40% of the world's leading technology-focused organizations as well as a growing number of emerging information technology companies. Here's why. We understand the risks facing companies that operate in an environment where innovation is a business imperative, not a lofty goal. Our technology specialists can help you build a portfolio of property insurance products and loss prevention services to protect your software and hardware as well as your facilities. We offer third-party insurance solutions such as errors and omissions insurance and intellectual property insurance to help protect your company's bottom line from the financial devastation of a lawsuit. Chubb's loss control and claim professionals have the technical skills and the industry specific knowledge to respond to your needs. And, our global network of 135 offices in 31 countries ensures that we do business wherever you do business.

From a system crash to a class action lawsuit, Chubb offers a dynamic approach to your insurance needs. Talk to your independent agent or broker or contact the Chubb Cincinnati office at (513) 721-0601.



### COVERAGE BEYOND YOUR EXPECTATIONS

Chubb's property/casualty program is endorsed by the American Electronics Association.

# **Furniture Solutions**

## Residential Furniture Rental

Bring your personal style and Fashion will furnish your home or apartment quickly and affordably.





Office Furniture Rental

# **Corporate Housing**

## Don't Want To Call Us Now?

Perhaps 30 Days In A Hotel Room Will Change Your Mind.

If you're looking for imaginative solutions, energetic employees and bottom line happiness, you better look beyond a hotel.

So for long-term stays, make a call for longterm comfort. Call The Pidgeon Company, official provider for Biocom members.





www.fashionfurniture.com

Conserve capital by renting furniture. Flexible programs can shrink and grow as your business demands.



One Call. One Bill. Greater Productivity.

(800) 578-6111 www.pidgeon.com



#### **Co-Chairs**

**Terrance J. Bruggeman** Chairman, President and CEO, Provasis Therapeutics, Inc.

Guy lannuzzi President and CEO, Mentus

Tina S. Nova, Ph.D Chief Executive Officer, Genoptix, Inc.

#### **Steering Committee**

**Stephen Ferruolo** Shareholder, Heller Ehrman White & McAuliffe LLP

**Brantley Haigh** Business Development Officer, Canadian Consulate General

**David F. Hale** President and CEO, CancerVax Corporation

**Trindl L. Reeves** Managing Director, Marsh Risk and Insurance Services

**Theodore D. Roth** President, Alliance Pharmaceutical Corp.

Larry G. Stambaugh Chairman, President and CEO, Maxim Pharmaceuticals, Inc.

**Julie Meier Wright** President, San Diego Regional Economic Development Corp.

#### **Sponsorship Committee**

**Terrance J. Bruggeman** Chairman, President and CEO, Provasis Therapeutics, Inc.

**Steven B. Engle** Chairman, President and CEO, La Jolla Pharmaceutical Company

Lisa Haile, Ph.D. Partner, Gray Cary Ware & Freidenrich

**Trindl L. Reeves** Managing Director, Marsh Risk and Insurance Services

Larry G. Stambaugh Chairman, President and CEO, Maxim Pharmaceuticals, Inc.

### Program Committee

Stephen M. W. Chang, Ph.D. Vice President and Chief Scientific Officer, Schering-Plough Research Institute and Canji, Inc.

**Donald W. Grimm** Venture Partner, HamiltonApex Technology Ventures

Bente Hansen, Ph.D. Principal, Bente Hansen and Associates

Guy lannuzzi President and CEO, Mentus

Bernard D. King, M.D. Principal, Macnas Consulting International

Steven J. Mento, Ph.D. President and CEO, Idun Pharmaceuticals Inc.

**C. Richard Piazza** 

David Shapiro, M.D. Executive Vice President, Chief Medical Officer, Idun Pharmaceuticals Inc.

#### **BIOCOM**/san diego Staff

Joseph D. Panetta President and CEO

**Timothy Biddle** Director of Membership and Business Development

**April Bailey** Associate Director of Public Policy

Liisa Bozinovic Associate Director of Finance and Operations

Jennifer Landress, CMP Associate Director of Events

Alison Raphael, CMP Events and Meetings Manager

Linda Wise Membership Manager

Kathleen Roll Coordinator of Education Programs

Melissa Guidi Executive Assistant

#### **Christine Scullion**

Corporate Support, Purchasing Group

#### **Shaye Testagrossa**

Corporate Support

Maxim Pharmaceuticals proudly sponsors the CALBIO Summit 2002 -Advancing the Business of Health

Maxim is a global biopharmaceutical company with a diverse pipeline of therapeutic candidates for life-threatening cancers and hepatitis.



#### PHARMACEUTICALS

8899 University Center Lane, Suite 400, San Diego, CA 92122 858.453.4040 www.maxim.com

BIOCOM/san diego is the regional association for the biotechnology and medical device companies in the San Diego area. In addition, BIOCOM includes a significant service sector of companies specialized in serving San Diego's growing life science industry. Since 1995 the organization has proactively addressed significant business and legislative issues, educated the general public, and developed programs to help life science companies operate efficiently and economically.


BIOCOM is actively engaged in ensuring that the life science industry remains a strong and growing part of the region's economy. The association is sanctioned by its members to facilitate public policy advocacy on a local, regional and statewide level, provide capital formation opportunities, promote the industry within the community, provide networking opportunities, organize meetings and conferences, provide professional development programs, communicate news and information and administrate member benefits such as the BIOCOM/san diego Purchasing Group.

#### San Diego Life Science

The San Diego life science community is dynamic and entrepreneurial! Highly concentrated and diverse, the region is one of the most prominent life science centers in the world. San Diego produces 9% of all sales and drug revenue in the United States with revenue at \$874 million and research and development expenditures at \$555 million. Among life science executives, San Diego quality of life is ranked number one and our workforce is ranked third nationwide. San Diego boasts the highest number of NIH grants per capita in the nation and most importantly, San Diego has in residence, the highest number of science-based Nobel winners in the world – eight!

#### **Membership Information**

BIOCOM/san diego invites you to learn more about the ways we can get you connected to our region's life science industry. If you would like more information on BIOCOM or the life sciences industry in San Diego please contact Linda Wise, Membership Manager, at (858) 455-0300, x222.




Effort is no substitute for knowledge

No matter how hard a law firm works, if it doesn't take the time to understand the forces that shape your business and your industry, the effort might be wasted. With years of experience assisting businesses in the life sciences sector, Foley & Lardner has already taken the time. With a structure based on our clients' business needs, we're nimble enough to anticipate business issues before they become problems. And with nearly 1000 attorneys pulling for you, you get more than just legal opinions. You get business solutions. To learn more, call Ken Klein at 619.685.6449 or visit our Web site at www.foleylardner.com.

## FOLEY LARDNER

CALBIOsummit 2002 41



Apoptosis: Commercial Opportunities will blend cutting edge knowledge of the molecular biology of the apoptosis pathway with its commercial applications in the pharmaceutical, diagnostic and agricultural fields.

#### **Topics**

Cancer Cardiovascular Disease **CNS** Disease Infectious Disease Inflammation And Others

#### **Speakers**


H. Robert Horvitz, MIT (Keynote) John Alam, Vertex (Keynote) Robert Armstrong, Idun Pharmaceuticals Avi Ashkenazi, Genentech Kenneth Bauer, Chromavision Medical Systems Martin Bennett, University of Cambridge Kenneth Chien, UCSD Martin Dickman, University of Nebraska Lincoln Gerard Evan, UCSF Robert Friedlander, Harvard Douglas Green, La Jolla Institute for Allergy and Immunology Leo Hofstra, University of Maastricht Richard Kitsis, Albert Einstein College of Medicine Eric LaCasse, Aegera Stuart Lipton, The Burnham Institute Donald Nicholson, Merck Frosst Edward Olejnczak, Abbott Oliver Press, University of Washington Guy Salvesen, The Burnham Institute Gordon Shore, Gemin X Andreas Strasser, WEHI W. Joseph Thompson, Cell Pathways Xiaodong Wang, University of Texas Southwestern Medical Center Raymond Warrell, Genta

#### For more information

www.idun.com or call 858/623-1330 Co-organizers: John Reed, The Burnham Institute Kevin Tomaselli, Idun Pharmaceuticals, Inc.



idun



Mayer, Brown, Rowe & Maw Berlin Brussels Charlotte Chicago Cologne Frankfurt Houston London Los Angeles Manchester New York Palo Alto Paris Washington www.mayerbrownrowe.com/biotech

# See The Future.

## Web-based Solutions from BioSpace

#### Clinical Competitive Intelligence System

A comprehensive tracking tool for life sciences professionals

- Real-time, easy access to clinical development information
- Links to news from key clinical and business sources
- Personalized search and browse capabilities

#### The BioSpace LInKS<sup>™</sup> Solution

A valuable tool to manage information overload and find important data

- Aggregates and Manages internal, subscription and public data sources
- Innovative and powerful search, collaboration and contextualization features
   Designed by and for life sciences professionals to accelerate the pace of innovation

To **discover** more, call us at (415) 355-6500. Or visit our Website at **WWW.biospace.com** 



BioSpace

J BioSpace

© 2002 BioSpace, Inc. All Rights Reserved

The ultimate life science executive gathering honoring leaders in San Diego's life science sector

# JUNE 24 2002 THE OLD GLOBE THEATRE

Join The T Sector and BIOCOM/San Diego at bioFUSION 2002, a celebration of the local life science industry, featuring the San Diego Life Science Achievement & Innovation Awards.


GOLD-SPONSORED BY:
PRICEWATERHOUSECOOPERS

The T Sector & BIOCOM/san diego

are proud to present the second annual

FOR MORE INFORMATION, CONTACT: KATHERINE HARRINGTON, PUBLISHER KHARRINGTON@THETSECTOR.COM | 619.447.3046





# What happens when your growth outpaces your bank's resources?

In the technology world, everything moves fast. You need a bank that can move just as fast. A bank that knows your business and how it works. That bank is Comerica. Our Technology and Life Sciences Division has what it takes to help you through all stages of your company's life cycle. At the pace your business is growing, now more than ever, you need Comerica. The bank you can start with. Grow with. And stay with.

Technology and Life Sciences Division



#### 800-226-2695



#### We listen. We understand. We make it work."

#### Comerica Bank-California. Member FDIC. Equal Opportunity Lender.

www.comerica.com


# Your next big discovery, BIO 2002.

# LIFEADVANCES<sup>M</sup>

This June, the best minds in biotechnology will converge on BIO 2002 to discover...

- The world's largest biotechnology event
- 17 concurrent educational tracks
- Over 250 hours of sessions featuring 850 speakers
- More than 750 exhibitors, showcasing the latest technologies

- Nightly networking receptions
- Plenary breakfasts and luncheons featuring industry luminaries
- Three full days of presentations during the Business Forum
- More than 14,000 delegates from over 46 countries






June 9-12, 2002 Toronto, Ontario, Canada Metro Toronto Convention Centre



### SAVE \$300 ON BIO 2002 - REGISTER ONLINE AT www.bio2002.org

# Partners for Life.





At Sun Microsystems<sup>™</sup> we recognize that no company works alone in the life sciences community. That's why, as a leader in the field, we work with the foremost hardware and software vendors, systems integrators, standards bodies, academic organizations, and customers in developing solutions that deliver IT therapeutics for the global life science community. Drop by our booth and let us show you how we can improve your life in life sciences.

www.sun.com/lifesciences

© 2002 Sun Microsystems, Inc. All rights reserved /Sun, Sun Microsystems, and the Sun logo, are trademarks or registered trademarks of Sun Microsystems, Inc., in the United States and other countries.

